• About Us
  • Technology
  • Partnering
  • News
  • Career

In the News

Categories:

Show All Press Release

May 8. 2024 / Press Release

Athebio AG appoints Thomas Huber, PhD, as CEO

Read more

December 15. 2023 / Press Release

Athebio AG appoints Dr. Jens Hennecke to its Board of Directors

Read more

September 18. 2023 / Press Release

POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands

Read more

July 20. 2023 / Press Release

Shareholders of Athebio AG elect Dr. Hans-Peter Gerber as new member of the Board of Directors

Read more

March 28. 2023 / Press Release

Athebio Enters Development and License Agreement with Acuitas Therapeutics

Read more

March 20. 2023 / Press Release

Athebio AG appoints Dr. Hans-Peter Gerber as Scientific Advisor

Read more

September 15. 2022 / Press Release

Athebio Enters Collaboration Agreement with 3T Biosciences

Read more

February 4. 2022 / Press Release

Athebio Enters Research Agreement with REGENXBIO

Read more

January 6. 2022 / Press Release

Athebio AG appoints Dr. Victor Levitsky as Scientific Adviso

Read more

  • About Us
  • Partnering
  • Technology
  • News
  • Contact Us

Contact

hello@athebio.com

+41 44 508 08 28

Location

Wagistrasse 18
8952 Zurich-Schlieren
Switzerland

© 2022 ATHEBIO
  • Imprint
  • Privacy